Danaher Q4: EPS Miss Expectations Amid Diagnostics Segment Lag

Zinger Key Points

Danaher Corporation DHR shares are trading lower in the premarket session on Wednesday.

The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of $2.16. Quarterly sales of $6.54 billion (+2%) beat the analyst consensus estimate of $6.42 billion.

The Biotechnology segment gained 6.5% year over year in the quarter under review, while the Life Sciences segment rose 5.5%. The Diagnostics segment sales decreased by 3% year over year.

The company exited the quarter with cash and equivalents worth $2.078 billion, and inventories worth $2.330 billion.

Also Read: Nasdaq Jumps 2% After Nvidia, Other Tech Stocks Bounce Back From DeepSeek Hit: Greed Index Remains In ‘Fear’ Zone

Danaher’s long-term debt as of quarter end totaled $15.50 billion. Operating cash flow was $2.0 billion in the fourth quarter and non-GAAP free cash flow was $1.5 billion.

Rainer M. Blair, President and Chief Executive Officer, stated, “Good execution by our team also drove solid cash flow and operating margin expansion.”

Outlook: Danaher expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter.

However, it anticipates a 3% year-over-year increase in core revenue for the full year of 2025.

Blair continued, “Looking ahead, we believe Danaher is better positioned than at any point in our 40-year history”. 

“The transformation in our portfolio over the last several years has created a focused life sciences and diagnostics innovator, poised for higher long-term growth, expanded margins and stronger cash flow.”

Price Action: DHR shares are trading lower by 5.48% to $234.26 premarket at last check Wednesday.

Read Next:

Photo via Shutterstock.

DHR Logo
DHRDanaher Corp
$199.051.19%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
25.19
Growth
38.49
Quality
32.72
Value
16.06
Price Trend
Short
Medium
Long
Got Questions? Ask
Which biotechnology companies could thrive?
How will life sciences firms react to Danaher's results?
What impact on diagnostics market from Danaher's decline?
Are there opportunities in cash flow stocks now?
How might long-term debt affect Danaher’s future?
Which healthcare ETFs could benefit from Danaher's transformation?
Is there potential in emerging biotech startups post-Danaher?
How will investors respond to declining revenue forecasts?
What competitive edges do focused innovators have?
Could Danaher’s stock present a buying opportunity?
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Comments
Loading...